BRAF and Ehlers-Danlos syndrome, musculocontractural type: Moreover, in line with the notion that B-raf inhibition by vemurafenib is effective on BRAFV600E-mutated ATCs [62–65], PLX4032 markedly reduces pErk and cell viability of ATC cells (Fig. 6c), likewise the treatment with trametinib, an FDA-approved MEK inhibitor (MEKi) for ATC (Supplementary Fig. S8B).